Neprilysin inhibition, endorphin dynamics, and early symptomatic improvement in heart failure: a pilot study

AIM: Sacubitril/valsartan is a first‐in‐class angiotensin receptor‐neprilysin inhibitor developed for the treatment of heart failure with reduced ejection fraction. Its benefits are achieved through the inhibition of neprilysin (NEP) and the specific blockade of the angiotensin receptor AT1. The man...

Descripción completa

Detalles Bibliográficos
Autores principales: Revuelta‐López, Elena, Núñez, Julio, Gastelurrutia, Paloma, Cediel, Germán, Januzzi, James L., Ibrahim, Nasrien E., Emdin, Michele, VanKimmenade, Roland, Pascual‐Figal, Domingo, Núñez, Eduardo, Gommans, Frank, Lupón, Josep, Bayés‐Genís, Antoni
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7160502/
https://www.ncbi.nlm.nih.gov/pubmed/32045114
http://dx.doi.org/10.1002/ehf2.12607

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7160502/
https://www.ncbi.nlm.nih.gov/pubmed/32045114
http://dx.doi.org/10.1002/ehf2.12607

Ejemplares similares